Finasteride Tablet, Film Coated
Product Images NDC 68071-3354

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3354). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3354 9

Finasteride 5 mg oral tablets packaging label from NuCare Pharmaceuticals, Inc. The label shows a quantity of 90 tablets and includes the NDC 68071-3354-9. It instructs to see the manufacturer's label for a full list of ingredients and includes warnings such as keeping the product out of reach of children and storing at controlled temperature 68-77°F. Manufacturer details include Intas Pharmaceuticals Limited, India.*

FDA Label Image

Structure (Finasteride Fig 1)

Chemical structure of finasteride, the active ingredient in the pharmaceutical product Finasteride 5 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The structure shows the steroid backbone with specific functional groups including a ketone and an amide with a tertiary butyl group.*

FDA Label Image

Image Of Figure 1 (Finasteride Fig 2)

A line graph displaying the mean change from baseline with 1 standard error over a period of four years for two groups: Placebo and Finasteride. The x-axis represents time points from baseline through years 1 to 4, while the y-axis shows the mean change values. The graph illustrates that the Finasteride group experiences a greater decrease in the measured variable over time compared to the Placebo group, with sample sizes noted at each time point.*

FDA Label Image

Image Of Figure 2 (Finasteride Fig 3)

A line graph showing the cumulative percent of patients over observation time in months for two groups: Finasteride and Placebo. Finasteride group shows a lower cumulative percent compared to Placebo. Below the graph is a table listing the number of events (cumulative) and number of patients at risk per year for both groups across various observation times.*

FDA Label Image

Image Of Figure 3 (Finasteride Fig 4)

A line graph comparing mean percent change from baseline over four years between placebo and finasteride groups. The x-axis represents time points from baseline through year 4, while the y-axis shows mean percent change values. The placebo group shows a downward trend, reaching approximately -15%, while the finasteride group shows an upward trend, reaching about +15%, both with error bars indicating standard error.*

FDA Label Image

Image Of Figure 4 (Finasteride Fig 5)

A line graph showing the percent with event over time in years from randomization. The graph compares four groups labeled Placebo, Finasteride, Doxazosin, and Combination, illustrating event occurrence rates across approximately 5.5 years.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.